Durg Coated Balloon Angioplasty in Infrapopliteal Lesions

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLiyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

About this trial

This study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (DCB) angioplasty for below the knee arterial lesions in patients critical with Limb Threatening Ischemia (CLTI).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Rutherford grade 4-6.

Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up.

Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries >20 mm. Lesions should not extend beyond the ankle joint.

Successful wire crossing of the lesion. After the pre-dilation of the ordinary balloon, the angiography showed that there was continuous blood flow.

Disqualifiers

Blood flow was not successfully reestablished.

Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.

Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.

Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.

Trial population

Patients suffered with Chronic Limb Theratening Ischemia and with significant infrapopliteal artery lesions.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • drug-coated balloon

    Device

    To evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Primary sustained clinical improvement at 12 months post-procedure

Primary sustained clinical improvement was defined as an upward shift on the Rutherford classification (Appendix) to a level of intermittent claudication without the need for repeated TLR in surviving patients without the need for unplanned amputation.

Time frame
12 months
2

Freedom of major limb adverse events at 12 months post-procedure

Major limb adverse events were defined as the composite of clinically-driven target lesion revascularization (CD-TLR); unplanned, unavoidable major amputation of the index limb; and treatment caused death.

Time frame
12 months

Secondary outcomes

1

Patency of the target lesions at 1 month, 3 months, 6 months and 12 months post-interventional

Patency includes the absence of clinically driven target lesion revascularization and/or recurrent target lesion diameter stenosis ≥50% by imaging (e.g., invasive angiography or, most commonly, duplex ultrasonography).

Time frame
1 month, 3 months, 6 months, 12 months
2

Procedural success rate

Procedural success for peripheral revascularization is defined as both technical success and absence of major adverse events (e.g., death, stroke, myocardial infarction, acute onset of limb ischemia, index bypass graft or treated segment thrombosis, and/or need for urgent/emergent vascular surgery) within 72 hours of the index procedure.

Time frame
72 hours
3

Vascular quality of life questionnaire(VascuQol)

The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life. 1 month, 3 months, 6 months, 12 months

Time frame
1 month, 3 months, 6 months, 12 months
4

Wound healing rate

Wound healing in patients with Rutherford grade 5.

Time frame
1 month, 3 months, 6 months, 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Lead sponsor

Xuanwu Hospital, Beijing

Collaborator

RenJi Hospital

Collaborator

Zhejiang University

Collaborator

First People's Hospital of Hangzhou

Collaborator

Second Affiliated Hospital of Suzhou University

Collaborator

Qingdao University

Collaborator

Chengdu University of Traditional Chinese Medicine

Collaborator

Shanghai Zhongshan Hospital

Collaborator

Huashan Hospital

Collaborator